A detailed history of Redmile Group, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,484,380 shares of COGT stock, worth $35.2 Million. This represents 3.17% of its overall portfolio holdings.

Number of Shares
4,484,380
Previous 4,799,973 6.57%
Holding current value
$35.2 Million
Previous $40.5 Million 19.69%
% of portfolio
3.17%
Previous 2.64%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.24 - $11.48 $2.6 Million - $3.62 Million
-315,593 Reduced 6.57%
4,484,380 $48.4 Million
Q2 2024

Aug 14, 2024

BUY
$6.01 - $9.04 $5.03 Million - $7.57 Million
837,371 Added 21.13%
4,799,973 $40.5 Million
Q1 2024

May 15, 2024

BUY
$4.38 - $9.02 $4.59 Million - $9.46 Million
1,048,580 Added 35.98%
3,962,602 $26.6 Million
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $3.49 Million - $8.68 Million
860,689 Added 41.92%
2,914,022 $17.1 Million
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.24 $20.2 Million - $27.2 Million
2,053,333 New
2,053,333 $24.3 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $516M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.